Chinese expert consensus on endocrine therapy for breast cancer (2026 edition) | Synapse
March 3, 2026Open Access
Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)
Key Points
Individualized treatment for HR-positive breast cancer is emphasized, enabling better patient outcomes.
The clinical guidance aims to standardize the application of endocrine therapy, improving treatment efficacy.
The consensus reflects current expert opinions and practices in the management of breast cancer.
Adopting this guidance may lead to more precise therapeutic approaches and improved patient care.
Abstract
This consensus may provide clinical guidance for the standardized application of ET, thereby facilitating precise and individualized treatment for HR-positive breast cancer.